{"abstracts-retrieval-response": {"item": {"ait:process-info": {"ait:status": {"@state": "update", "@type": "core", "@stage": "S300"}, "ait:date-delivered": {"@day": "05", "@year": "2023", "@timestamp": "2023-07-05T02:45:07.000007-04:00", "@month": "07"}, "ait:date-sort": {"@day": "01", "@year": "2016", "@month": "08"}}, "xocs:meta": {"xocs:funding-list": {"@pui-match": "primary", "@has-funding-info": "1", "xocs:funding": [{"xocs:funding-agency-matched-string": "Chinese Thoracic Oncology Group", "xocs:funding-id": "CTONG0902"}, {"xocs:funding-agency-matched-string": "F. Hoffmann-La Roche Ltd.", "xocs:funding-agency": "F. Hoffmann-La Roche", "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100007013", "xocs:funding-agency-country": "http://sws.geonames.org/2658434/"}], "xocs:funding-addon-generated-timestamp": "2021-06-01T16:17:11.896Z", "xocs:funding-text": "The study was sponsored by F. Hoffmann-La Roche Ltd., the Chinese Thoracic Oncology Group (CTONG0902), and the Lung Cancer Research Group . Support for third-party writing assistance for this manuscript was funded by F. Hoffmann-La Roche Ltd.", "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"}}, "bibrecord": {"head": {"author-group": [{"affiliation": {"country": "Hong Kong", "@afid": "60002798", "@country": "hkg", "city": "Shatin, New Territories", "organization": [{"$": "State Key Laboratory of Southern China"}, {"$": "Department of Clinical Oncology"}, {"$": "Chinese University of Hong Kong"}], "affiliation-id": {"@afid": "60002798", "@dptid": "113387205"}, "@dptid": "113387205"}, "author": [{"ce:given-name": "Tony", "preferred-name": {"ce:given-name": "Tony", "ce:initials": "T.", "ce:surname": "Mok", "ce:indexed-name": "Mok T."}, "@seq": "1", "ce:initials": "T.", "@date-locked": "2019-02-12T23:17:08.289", "@_fa": "true", "@type": "auth", "ce:surname": "Mok", "@auid": "7006561460", "ce:indexed-name": "Mok T."}]}, {"affiliation": {"country": "Philippines", "address-part": "Quezon Ave., Diliman", "@afid": "60071470", "@country": "phl", "city": "Quezon City, Metro Manila", "organization": {"$": "Lung Center of the Philippines"}, "affiliation-id": {"@afid": "60071470"}}, "author": [{"ce:given-name": "Guia", "preferred-name": {"ce:given-name": "Guia", "ce:initials": "G.", "ce:surname": "Ladrera", "ce:indexed-name": "Ladrera G."}, "@seq": "2", "ce:initials": "G.", "@_fa": "true", "@type": "auth", "ce:surname": "Ladrera", "@auid": "56287672600", "ce:indexed-name": "Ladrera G."}]}, {"affiliation": {"country": "Thailand", "address-part": "2 Wanglang Road", "postal-code": "10700", "@afid": "60199575", "@country": "tha", "city": "Bangkok, Bangkoknoi", "organization": {"$": "Siriraj Hospital"}, "affiliation-id": {"@afid": "60199575"}}, "author": [{"ce:given-name": "Vichien", "preferred-name": {"ce:given-name": "Vichien", "ce:initials": "V.", "ce:surname": "Srimuninnimit", "ce:indexed-name": "Srimuninnimit V."}, "@seq": "3", "ce:initials": "V.", "@_fa": "true", "@type": "auth", "ce:surname": "Srimuninnimit", "@auid": "6602745742", "ce:indexed-name": "Srimuninnimit V."}]}, {"affiliation": {"country": "Thailand", "address-part": "1873 Rama 4 Road", "postal-code": "10330", "@afid": "60022183", "@country": "tha", "city": "Bangkok, Pathumwan", "organization": {"$": "King Chulalongkorn Memorial Hospital"}, "affiliation-id": {"@afid": "60022183"}}, "author": [{"ce:given-name": "Virote", "preferred-name": {"ce:given-name": "Virote", "ce:initials": "V.", "ce:surname": "Sriuranpong", "ce:indexed-name": "Sriuranpong V."}, "@seq": "4", "ce:initials": "V.", "@_fa": "true", "@type": "auth", "ce:surname": "Sriuranpong", "@auid": "6603599644", "ce:indexed-name": "Sriuranpong V."}]}, {"affiliation": {"country": "Taiwan", "address-part": "No. 7, Zhongshan S Rd.", "@afid": "60073385", "@country": "twn", "city": "Zhongzheng District, Taipei", "organization": {"$": "National Taiwan University Hospital"}, "affiliation-id": {"@afid": "60073385"}}, "author": [{"ce:given-name": "Chong-Jen", "preferred-name": {"ce:given-name": "Chong Jen", "ce:initials": "C.J.", "ce:surname": "Yu", "ce:indexed-name": "Yu C.J."}, "@seq": "5", "ce:initials": "C.-J.", "@_fa": "true", "@type": "auth", "ce:surname": "Yu", "@auid": "7404977466", "ce:indexed-name": "Yu C.-J."}]}, {"affiliation": {"country": "Thailand", "@afid": "60000881", "@country": "tha", "city": "Chiang Mai", "organization": [{"$": "Faculty of Medicine"}, {"$": "Chiangmai University"}], "affiliation-id": {"@afid": "60000881"}}, "author": [{"ce:given-name": "Sumitra", "preferred-name": {"ce:given-name": "Sumitra", "ce:initials": "S.", "ce:surname": "Thongprasert", "ce:indexed-name": "Thongprasert S."}, "@seq": "6", "ce:initials": "S.", "@_fa": "true", "@type": "auth", "ce:surname": "Thongprasert", "@auid": "7003592958", "ce:indexed-name": "Thongprasert S."}]}, {"affiliation": {"country": "Philippines", "address-part": "Taft Avenue Ermita, Brgy 670 Zone 72", "postal-code": "1000", "@afid": "60071478", "@country": "phl", "city": "Manila, Metro Manila", "organization": {"$": "Philippine General Hospital"}, "affiliation-id": {"@afid": "60071478"}}, "author": [{"ce:given-name": "Jennifer", "preferred-name": {"ce:given-name": "Jennifer", "ce:initials": "J.", "ce:surname": "Sandoval-Tan", "ce:indexed-name": "Sandoval-Tan J."}, "@seq": "7", "ce:initials": "J.", "@_fa": "true", "@type": "auth", "ce:surname": "Sandoval-Tan", "@auid": "55762538000", "ce:indexed-name": "Sandoval-Tan J."}]}, {"affiliation": {"country": "South Korea", "@afid": "60068716", "@country": "kor", "city": "Goyang", "organization": {"$": "National Cancer Center"}, "affiliation-id": {"@afid": "60068716"}}, "author": [{"ce:given-name": "Jin Soo", "preferred-name": {"ce:given-name": "Jin Soo", "ce:initials": "J.S.", "ce:surname": "Lee", "ce:indexed-name": "Lee J.S."}, "@seq": "8", "ce:initials": "J.S.", "@_fa": "true", "@type": "auth", "ce:surname": "Lee", "@auid": "42161717300", "ce:indexed-name": "Lee J.S."}]}, {"affiliation": {"country": "Philippines", "address-part": "Pasig Blvd", "@afid": "127844345", "@country": "phl", "city": "Pasig, Metro Manila", "organization": {"$": "Rizal Medical Center"}, "affiliation-id": {"@afid": "127844345"}}, "author": [{"ce:given-name": "Fatima", "preferred-name": {"ce:given-name": "Fatima", "ce:initials": "F.", "ce:surname": "Fuerte", "ce:indexed-name": "Fuerte F."}, "@seq": "9", "ce:initials": "F.", "@_fa": "true", "@type": "auth", "ce:surname": "Fuerte", "@auid": "55762400200", "ce:indexed-name": "Fuerte F."}]}, {"affiliation": {"country": "United States", "postal-code": "94080", "@afid": "60026209", "@country": "usa", "city": "South San Francisco", "organization": [{"$": "Oncology Biomarker Development"}, {"$": "Genentech Inc."}], "affiliation-id": {"@afid": "60026209", "@dptid": "109450933"}, "state": "CA", "@dptid": "109450933"}, "author": [{"ce:given-name": "David S.", "preferred-name": {"ce:given-name": "David S.", "ce:initials": "D.S.", "ce:surname": "Shames", "ce:indexed-name": "Shames D.S."}, "@seq": "10", "ce:initials": "D.S.", "@_fa": "true", "@type": "auth", "ce:surname": "Shames", "@auid": "34573130000", "ce:indexed-name": "Shames D.S."}]}, {"affiliation": {"country": "Switzerland", "@afid": "60008201", "@country": "che", "city": "Basel", "organization": {"$": "F. Hoffmann-La Roche Ltd."}, "affiliation-id": {"@afid": "60008201"}}, "author": [{"ce:given-name": "Barbara", "preferred-name": {"ce:given-name": "Barbara", "ce:initials": "B.", "ce:surname": "Klughammer", "ce:indexed-name": "Klughammer B."}, "@seq": "11", "ce:initials": "B.", "@date-locked": "2018-04-18T11:45:04.623", "@_fa": "true", "@type": "auth", "ce:surname": "Klughammer", "@auid": "36777629300", "ce:indexed-name": "Klughammer B."}, {"ce:given-name": "Matt", "preferred-name": {"ce:given-name": "Matt", "ce:initials": "M.", "ce:surname": "Truman", "ce:indexed-name": "Truman M."}, "@seq": "12", "ce:initials": "M.", "@_fa": "true", "@type": "auth", "ce:surname": "Truman", "@auid": "57189251756", "ce:indexed-name": "Truman M."}, {"ce:given-name": "Pablo", "preferred-name": {"ce:given-name": "Pablo", "ce:initials": "P.", "ce:surname": "Perez-Moreno", "ce:indexed-name": "Perez-Moreno P."}, "@seq": "13", "ce:initials": "P.", "@_fa": "true", "@type": "auth", "ce:surname": "Perez-Moreno", "@auid": "54397369600", "ce:indexed-name": "Perez-Moreno P."}]}, {"affiliation": {"country": "China", "@afid": "60069718", "@country": "chn", "city": "Guangzhou", "organization": [{"$": "Guangdong Lung Cancer Institute"}, {"$": "Guangdong General Hospital"}, {"$": "Guangdong Academy of Medical Sciences"}], "affiliation-id": {"@afid": "60069718", "@dptid": "109576787"}, "@dptid": "109576787"}, "author": [{"ce:given-name": "Yi-Long", "preferred-name": {"ce:given-name": "Yi Long", "ce:initials": "Y.L.", "ce:surname": "Wu", "ce:indexed-name": "Wu Y.L."}, "@seq": "14", "ce:initials": "Y.-L.", "@date-locked": "2018-05-26T14:42:32.420", "@_fa": "true", "@type": "auth", "ce:surname": "Wu", "@auid": "55569782000", "@orcid": "0000-0002-3611-0258", "ce:indexed-name": "Wu Y.-L."}]}], "citation-title": "Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer", "abstracts": "\u00a9 2016 The Authors.Objectives: The FASTACT-2 study of intercalated erlotinib with chemotherapy in Asian patients found that EGFR mutations were the main driver behind the significant progression-free survival (PFS) benefit noted in the overall population. Further exploratory biomarker analyses were conducted to provide additional insight. Materials and methods: This multicenter, randomized, placebo-controlled, double-blind, phase III study investigated intercalated first-line erlotinib or placebo with gemcitabine/platinum, followed by maintenance erlotinib or placebo, for patients with stage IIIB/IV non-small cell lung cancer (NSCLC). Provision of samples for biomarker analysis was encouraged but not mandatory. The following biomarkers were analyzed (in order of priority): EGFR mutation by cobas\u00ae test, KRAS mutation by cobas\u00ae KRAS test, HER2 by immunohistochemistry (IHC), HER3 by IHC, ERCC1 by IHC, EGFR gene copy number by fluorescence in-situ hybridization (FISH) and EGFR by IHC. All subgroups were assessed for PFS (primary endpoint), overall survival (OS), non-progression rate and objective response rate. Results: Overall, 256 patients provided samples for analysis. Considerable overlap was noted among biomarkers, except for EGFR and KRAS mutations, which are mutually exclusive. Other than EGFR mutations (p < 0.0001), no other biomarkers were significantly predictive of outcomes in a treatment-by-biomarker interaction test, although ERCC1 IHC-positive status was predictive of improved OS for the erlotinib arm versus placebo in EGFR wild-type patients (median 18.4 vs 9.5 months; hazard ratio [HR] HR = 0.32, 95% confidence intervals [CI]: 0.14-0.69, p = 0.0024). Conclusion: Activating EGFR mutations were predictive for improved treatment outcomes with a first-line intercalated regimen of chemotherapy and erlotinib in NSCLC. ERCC1 status may have some predictive value in EGFR wild-type disease, but requires further investigation.", "correspondence": {"affiliation": {"country": "Hong Kong", "@country": "hkg", "city": "Shatin, New Territories", "organization": [{"$": "State Key Laboratory of Southern China"}, {"$": "Department of Clinical Oncology"}, {"$": "Chinese University of Hong Kong"}]}, "person": {"ce:given-name": "Tony", "ce:initials": "T.", "ce:surname": "Mok", "ce:indexed-name": "Mok T."}}, "citation-info": {"author-keywords": {"author-keyword": [{"$": "Biomarkers", "@xml:lang": "eng"}, {"$": "EGFR", "@xml:lang": "eng"}, {"$": "Erlotinib", "@xml:lang": "eng"}, {"$": "NSCLC", "@xml:lang": "eng"}]}, "citation-type": {"@code": "ar"}, "citation-language": {"@language": "English", "@xml:lang": "eng"}, "abstract-language": {"@language": "English", "@xml:lang": "eng"}}, "source": {"website": {"ce:e-address": {"$": "www.elsevier.com/locate/lungcan", "@type": "email"}}, "translated-sourcetitle": {"$": "Lung Cancer", "@xml:lang": "eng"}, "volisspag": {"voliss": {"@volume": "98"}, "pagerange": {"@first": "1", "@last": "8"}}, "@type": "j", "sourcetitle": "Lung Cancer", "publicationdate": {"month": "08", "year": "2016", "date-text": {"@xfab-added": "true", "$": "1 August 2016"}, "day": "01"}, "codencode": "LUCAE", "sourcetitle-abbrev": "Lung Cancer", "@country": "irl", "issn": [{"$": "18728332", "@type": "electronic"}, {"$": "01695002", "@type": "print"}], "publicationyear": {"@first": "2016"}, "publisher": {"publishername": "Elsevier Ireland Ltd"}, "@srcid": "12391"}, "enhancement": {"classificationgroup": {"classifications": [{"@type": "CABSCLASS", "classification": [{"classification-code": "87.3", "classification-description": "CANCER RESEARCH; DIAGNOSIS AND PROGNOSIS"}, {"classification-code": "87.4.1", "classification-description": "CANCER RESEARCH; TREATMENT; Chemotherapy"}, {"classification-code": "87.5.7", "classification-description": "CANCER RESEARCH; CLINICAL INVESTIGATIONS BY ORGAN SITE; Lung"}]}, {"@type": "EMCLASS", "classification": [{"classification-code": "15", "classification-description": "Chest Diseases, Thoracic Surgery and Tuberculosis"}, {"classification-code": "16", "classification-description": "Cancer"}, {"classification-code": "22", "classification-description": "Human Genetics"}, {"classification-code": "29", "classification-description": "Clinical and Experimental Biochemistry"}, {"classification-code": "37", "classification-description": "Drug Literature Index"}]}, {"@type": "ASJC", "classification": [{"$": "2730"}, {"$": "2740"}, {"$": "1306"}]}, {"@type": "SUBJABBR", "classification": [{"$": "MEDI"}, {"$": "BIOC"}]}]}, "chemicalgroup": {"chemicals": [{"@source": "esbd", "chemical": [{"cas-registry-number": "41575-94-4", "chemical-name": "carboplatin"}, {"cas-registry-number": [{"$": "15663-27-1"}, {"$": "26035-31-4"}, {"$": "96081-74-2"}], "chemical-name": "cisplatin"}, {"cas-registry-number": "137632-09-8", "chemical-name": "epidermal growth factor receptor 2"}, {"cas-registry-number": "497121-54-7", "chemical-name": "epidermal growth factor receptor 3"}, {"cas-registry-number": [{"$": "183319-69-9"}, {"$": "183321-74-6"}], "chemical-name": "erlotinib"}, {"cas-registry-number": "103882-84-4", "chemical-name": "gemcitabine"}, {"cas-registry-number": "301253-48-5", "chemical-name": "vasculotropin receptor"}, {"cas-registry-number": "951-77-9", "chemical-name": "deoxycytidine"}, {"cas-registry-number": "7440-06-4", "chemical-name": "platinum"}]}, {"@source": "nlm", "chemical": [{"chemical-name": "Biomarkers, Tumor"}, {"chemical-name": "Deoxycytidine"}, {"chemical-name": "Erlotinib Hydrochloride"}, {"chemical-name": "gemcitabine"}, {"chemical-name": "Platinum"}]}]}}}, "item-info": {"copyright": {"$": "Copyright 2017 Elsevier B.V., All rights reserved.", "@type": "Elsevier"}, "dbcollection": [{"$": "CABS"}, {"$": "EMBASE"}, {"$": "MEDL"}, {"$": "REAXYSCAR"}, {"$": "RMC"}, {"$": "SCOPUS"}, {"$": "Scopusbase"}], "history": {"date-created": {"@day": "26", "@year": "2017", "@timestamp": "BST 16:50:12", "@month": "12"}}, "itemidlist": {"itemid": [{"$": "610342095", "@idtype": "PUI"}, {"$": "2016180410", "@idtype": "CABS"}, {"$": "650288160", "@idtype": "CAR-ID"}, {"$": "20160370683", "@idtype": "EMBASE"}, {"$": "27393499", "@idtype": "MEDL"}, {"$": "20161180412", "@idtype": "REAXYSCAR"}, {"$": "2016146670", "@idtype": "RMC"}, {"$": "84966701371", "@idtype": "SCP"}, {"$": "84966701371", "@idtype": "SGR"}, {"$": "619920669", "@idtype": "PUIsecondary"}], "ce:pii": "S0169500216303099", "ce:doi": "10.1016/j.lungcan.2016.04.023"}}, "tail": {"bibliography": {"@refcount": "27", "reference": [{"ref-fulltext": "Mok T., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361:947-957.", "@id": "1", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma"}, "refd-itemidlist": {"itemid": {"$": "69949162760", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "361"}, "pagerange": {"@first": "947", "@last": "957"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Mok", "ce:indexed-name": "Mok T."}, {"@seq": "2", "ce:initials": "Y.L.", "@_fa": "true", "ce:surname": "Wu", "ce:indexed-name": "Wu Y.L."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Thongprasert", "ce:indexed-name": "Thongprasert S."}, {"@seq": "4", "ce:initials": "C.H.", "@_fa": "true", "ce:surname": "Yang", "ce:indexed-name": "Yang C.H."}, {"@seq": "5", "ce:initials": "D.T.", "@_fa": "true", "ce:surname": "Chu", "ce:indexed-name": "Chu D.T."}, {"@seq": "6", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Saijo", "ce:indexed-name": "Saijo N."}], "et-al": null}, "ref-sourcetitle": "N. Engl. J. Med."}}, {"ref-fulltext": "Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011, 12:735-742.", "@id": "2", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study"}, "refd-itemidlist": {"itemid": {"$": "79960889662", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "12"}, "pagerange": {"@first": "735", "@last": "742"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Zhou", "ce:indexed-name": "Zhou C."}, {"@seq": "2", "ce:initials": "Y.L.", "@_fa": "true", "ce:surname": "Wu", "ce:indexed-name": "Wu Y.L."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Chen", "ce:indexed-name": "Chen G."}, {"@seq": "4", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Feng", "ce:indexed-name": "Feng J."}, {"@seq": "5", "ce:initials": "X.Q.", "@_fa": "true", "ce:surname": "Liu", "ce:indexed-name": "Liu X.Q."}, {"@seq": "6", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Wang", "ce:indexed-name": "Wang C."}], "et-al": null}, "ref-sourcetitle": "Lancet Oncol."}}, {"ref-fulltext": "Rosell R., Carcerency E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13:239-246.", "@id": "3", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial"}, "refd-itemidlist": {"itemid": {"$": "84857502654", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "13"}, "pagerange": {"@first": "239", "@last": "246"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Rosell", "ce:indexed-name": "Rosell R."}, {"@seq": "2", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Carcerency", "ce:indexed-name": "Carcerency E."}, {"@seq": "3", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Gervais", "ce:indexed-name": "Gervais R."}, {"@seq": "4", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Vergnenegre", "ce:indexed-name": "Vergnenegre A."}, {"@seq": "5", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Massuti", "ce:indexed-name": "Massuti B."}, {"@seq": "6", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Felip", "ce:indexed-name": "Felip E."}], "et-al": null}, "ref-sourcetitle": "Lancet Oncol."}}, {"ref-fulltext": "Xue C., Hu Z., Jiang W., Zhao Y., Xu F., Huang Y., et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer 2012, 77:371-375.", "@id": "4", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China"}, "refd-itemidlist": {"itemid": {"$": "84863775476", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "77"}, "pagerange": {"@first": "371", "@last": "375"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Xue", "ce:indexed-name": "Xue C."}, {"@seq": "2", "ce:initials": "Z.", "@_fa": "true", "ce:surname": "Hu", "ce:indexed-name": "Hu Z."}, {"@seq": "3", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Jiang", "ce:indexed-name": "Jiang W."}, {"@seq": "4", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Zhao", "ce:indexed-name": "Zhao Y."}, {"@seq": "5", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Xu", "ce:indexed-name": "Xu F."}, {"@seq": "6", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Huang", "ce:indexed-name": "Huang Y."}], "et-al": null}, "ref-sourcetitle": "Lung Cancer"}}, {"ref-fulltext": "Xu C., Zhou Q., Wu Y.L. Can EGFR TKIs be used in first-line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? A literature-based meta-analysis. J. Haematol. Oncol. 2012, 5:62-77.", "@id": "5", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Can EGFR TKIs be used in first-line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? A literature-based meta-analysis"}, "refd-itemidlist": {"itemid": {"$": "84867195295", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "5"}, "pagerange": {"@first": "62", "@last": "77"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Xu", "ce:indexed-name": "Xu C."}, {"@seq": "2", "ce:initials": "Q.", "@_fa": "true", "ce:surname": "Zhou", "ce:indexed-name": "Zhou Q."}, {"@seq": "3", "ce:initials": "Y.L.", "@_fa": "true", "ce:surname": "Wu", "ce:indexed-name": "Wu Y.L."}]}, "ref-sourcetitle": "J. Haematol. Oncol."}}, {"ref-fulltext": "Choi Y.L., Sun J.M., Cho J., Rampal S., Han J., Parasuraman B., et al. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS One 2013, 8:e56011.", "@id": "6", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital"}, "refd-itemidlist": {"itemid": [{"$": "e56011", "@idtype": "ARTNUM"}, {"$": "84874544125", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "8"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "Y.L.", "@_fa": "true", "ce:surname": "Choi", "ce:indexed-name": "Choi Y.L."}, {"@seq": "2", "ce:initials": "J.M.", "@_fa": "true", "ce:surname": "Sun", "ce:indexed-name": "Sun J.M."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Cho", "ce:indexed-name": "Cho J."}, {"@seq": "4", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Rampal", "ce:indexed-name": "Rampal S."}, {"@seq": "5", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Han", "ce:indexed-name": "Han J."}, {"@seq": "6", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Parasuraman", "ce:indexed-name": "Parasuraman B."}], "et-al": null}, "ref-sourcetitle": "PLoS One"}}, {"ref-fulltext": "Ellis P.M., Verma S., Sehdev S., Younas J., Leighl N. Implementation of a national EGFR testing strategy in a publicly funded health system. J. Thorac. Oncol. 2011, 6:S1513.", "@id": "7", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Implementation of a national EGFR testing strategy in a publicly funded health system"}, "refd-itemidlist": {"itemid": {"$": "84891735793", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "6"}, "pagerange": {"@first": "S1513"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.M.", "@_fa": "true", "ce:surname": "Ellis", "ce:indexed-name": "Ellis P.M."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Verma", "ce:indexed-name": "Verma S."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Sehdev", "ce:indexed-name": "Sehdev S."}, {"@seq": "4", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Younas", "ce:indexed-name": "Younas J."}, {"@seq": "5", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Leighl", "ce:indexed-name": "Leighl N."}]}, "ref-sourcetitle": "J. Thorac. Oncol."}}, {"ref-fulltext": "Mok T.S., Wu Y.L., Yu C.J., Zhou C., Chen Y.M., Zhang L., et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 2009, 27:5080-5087.", "@id": "8", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer"}, "refd-itemidlist": {"itemid": {"$": "75249084998", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "27"}, "pagerange": {"@first": "5080", "@last": "5087"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.S.", "@_fa": "true", "ce:surname": "Mok", "ce:indexed-name": "Mok T.S."}, {"@seq": "2", "ce:initials": "Y.L.", "@_fa": "true", "ce:surname": "Wu", "ce:indexed-name": "Wu Y.L."}, {"@seq": "3", "ce:initials": "C.J.", "@_fa": "true", "ce:surname": "Yu", "ce:indexed-name": "Yu C.J."}, {"@seq": "4", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Zhou", "ce:indexed-name": "Zhou C."}, {"@seq": "5", "ce:initials": "Y.M.", "@_fa": "true", "ce:surname": "Chen", "ce:indexed-name": "Chen Y.M."}, {"@seq": "6", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Zhang", "ce:indexed-name": "Zhang L."}], "et-al": null}, "ref-sourcetitle": "J. Clin. Oncol."}}, {"ref-fulltext": "Wu J.L., Lee J.S., Thongprasert S., Yu C.J., Zhang L., Ladrera G., et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013, 14:777-786.", "@id": "9", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial"}, "refd-itemidlist": {"itemid": {"$": "84879784343", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "14"}, "pagerange": {"@first": "777", "@last": "786"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.L.", "@_fa": "true", "ce:surname": "Wu", "ce:indexed-name": "Wu J.L."}, {"@seq": "2", "ce:initials": "J.S.", "@_fa": "true", "ce:surname": "Lee", "ce:indexed-name": "Lee J.S."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Thongprasert", "ce:indexed-name": "Thongprasert S."}, {"@seq": "4", "ce:initials": "C.J.", "@_fa": "true", "ce:surname": "Yu", "ce:indexed-name": "Yu C.J."}, {"@seq": "5", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Zhang", "ce:indexed-name": "Zhang L."}, {"@seq": "6", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Ladrera", "ce:indexed-name": "Ladrera G."}], "et-al": null}, "ref-sourcetitle": "Lancet Oncol."}}, {"ref-fulltext": "Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 2005, 23:5900-5909.", "@id": "10", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib"}, "refd-itemidlist": {"itemid": {"$": "24944497744", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "23"}, "pagerange": {"@first": "5900", "@last": "5909"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.A.", "@_fa": "true", "ce:surname": "Eberhard", "ce:indexed-name": "Eberhard D.A."}, {"@seq": "2", "ce:initials": "B.E.", "@_fa": "true", "ce:surname": "Johnson", "ce:indexed-name": "Johnson B.E."}, {"@seq": "3", "ce:initials": "L.C.", "@_fa": "true", "ce:surname": "Amler", "ce:indexed-name": "Amler L.C."}, {"@seq": "4", "ce:initials": "A.D.", "@_fa": "true", "ce:surname": "Goddard", "ce:indexed-name": "Goddard A.D."}, {"@seq": "5", "ce:initials": "S.L.", "@_fa": "true", "ce:surname": "Heldens", "ce:indexed-name": "Heldens S.L."}, {"@seq": "6", "ce:initials": "R.S.", "@_fa": "true", "ce:surname": "Herbst", "ce:indexed-name": "Herbst R.S."}], "et-al": null}, "ref-sourcetitle": "J. Clin. Oncol."}}, {"ref-fulltext": "Brugger W., Triller N., Blasinska-Morawiec M., Curescu S., Sakalauskas R., Manikhas G.M., et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2011, 29:4113-4120.", "@id": "11", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer"}, "refd-itemidlist": {"itemid": {"$": "80755181069", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "29"}, "pagerange": {"@first": "4113", "@last": "4120"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Brugger", "ce:indexed-name": "Brugger W."}, {"@seq": "2", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Triller", "ce:indexed-name": "Triller N."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Blasinska-Morawiec", "ce:indexed-name": "Blasinska-Morawiec M."}, {"@seq": "4", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Curescu", "ce:indexed-name": "Curescu S."}, {"@seq": "5", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Sakalauskas", "ce:indexed-name": "Sakalauskas R."}, {"@seq": "6", "ce:initials": "G.M.", "@_fa": "true", "ce:surname": "Manikhas", "ce:indexed-name": "Manikhas G.M."}], "et-al": null}, "ref-sourcetitle": "J. Clin. Oncol."}}, {"ref-fulltext": "Zhu C.-Q., da Cunha Santos G., Ding K., Sakurada A., Cutz J., C, Liu N., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 2008, 26:428-475.", "@id": "12", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21"}, "refd-itemidlist": {"itemid": {"$": "52049090365", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "26"}, "pagerange": {"@first": "428", "@last": "475"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.-Q.", "@_fa": "true", "ce:surname": "Zhu", "ce:indexed-name": "Zhu C.-Q."}, {"@seq": "2", "ce:initials": "G.", "@_fa": "true", "ce:surname": "da Cunha Santos", "ce:indexed-name": "da Cunha Santos G."}, {"@seq": "3", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Ding", "ce:indexed-name": "Ding K."}, {"@seq": "4", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Sakurada", "ce:indexed-name": "Sakurada A."}, {"@seq": "5", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Cutz", "ce:indexed-name": "Cutz J."}, {"@seq": "6", "@_fa": "true", "ce:surname": "C", "ce:indexed-name": "C"}, {"@seq": "7", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Liu", "ce:indexed-name": "Liu N."}], "et-al": null}, "ref-sourcetitle": "J. Clin. Oncol."}}, {"ref-fulltext": "Fukuoka M., Wu Y.-L., Thongprasert S., Sunpaweravong P., Leong S.S., Sriuranpong V., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 2011, 29:2866-2874.", "@id": "13", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)"}, "refd-itemidlist": {"itemid": {"$": "79960702788", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "29"}, "pagerange": {"@first": "2866", "@last": "2874"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Fukuoka", "ce:indexed-name": "Fukuoka M."}, {"@seq": "2", "ce:initials": "Y.-L.", "@_fa": "true", "ce:surname": "Wu", "ce:indexed-name": "Wu Y.-L."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Thongprasert", "ce:indexed-name": "Thongprasert S."}, {"@seq": "4", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Sunpaweravong", "ce:indexed-name": "Sunpaweravong P."}, {"@seq": "5", "ce:initials": "S.S.", "@_fa": "true", "ce:surname": "Leong", "ce:indexed-name": "Leong S.S."}, {"@seq": "6", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Sriuranpong", "ce:indexed-name": "Sriuranpong V."}], "et-al": null}, "ref-sourcetitle": "J. Clin. Oncol."}}, {"ref-fulltext": "Mazi\u00e8res J., Brugger W., Cappuzzo F., Middel P., Frosch A., Bara I., et al. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. Lung Cancer 2013, 82:231-237.", "@id": "14", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study"}, "refd-itemidlist": {"itemid": {"$": "84887016448", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "82"}, "pagerange": {"@first": "231", "@last": "237"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Mazi\u00e8res", "ce:indexed-name": "Mazieres J."}, {"@seq": "2", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Brugger", "ce:indexed-name": "Brugger W."}, {"@seq": "3", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Cappuzzo", "ce:indexed-name": "Cappuzzo F."}, {"@seq": "4", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Middel", "ce:indexed-name": "Middel P."}, {"@seq": "5", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Frosch", "ce:indexed-name": "Frosch A."}, {"@seq": "6", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Bara", "ce:indexed-name": "Bara I."}], "et-al": null}, "ref-sourcetitle": "Lung Cancer"}}, {"ref-fulltext": "Shankaran H., Zhang Y., Tan Y., Resat H. Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3. PLoS Comput. Biol. 2013, 9(8):e1003201.", "@id": "15", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3"}, "refd-itemidlist": {"itemid": [{"$": "e1003201", "@idtype": "ARTNUM"}, {"$": "84883416861", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "9", "@issue": "8"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Shankaran", "ce:indexed-name": "Shankaran H."}, {"@seq": "2", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Zhang", "ce:indexed-name": "Zhang Y."}, {"@seq": "3", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Tan", "ce:indexed-name": "Tan Y."}, {"@seq": "4", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Resat", "ce:indexed-name": "Resat H."}]}, "ref-sourcetitle": "PLoS Comput. Biol."}}, {"ref-fulltext": "Schaefer G., Haber L., Crocker L.M., Shia S., Shao L., Dowbenko D., et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011, 20:472-486.", "@id": "16", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies"}, "refd-itemidlist": {"itemid": {"$": "80054765331", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "20"}, "pagerange": {"@first": "472", "@last": "486"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Schaefer", "ce:indexed-name": "Schaefer G."}, {"@seq": "2", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Haber", "ce:indexed-name": "Haber L."}, {"@seq": "3", "ce:initials": "L.M.", "@_fa": "true", "ce:surname": "Crocker", "ce:indexed-name": "Crocker L.M."}, {"@seq": "4", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Shia", "ce:indexed-name": "Shia S."}, {"@seq": "5", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Shao", "ce:indexed-name": "Shao L."}, {"@seq": "6", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Dowbenko", "ce:indexed-name": "Dowbenko D."}], "et-al": null}, "ref-sourcetitle": "Cancer Cell"}}, {"ref-fulltext": "Wilson T.R., Lee D.Y., Berry L., Shames D.S., Settleman J. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 2011, 20:158-172.", "@id": "17", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers"}, "refd-itemidlist": {"itemid": {"$": "80051578430", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "20"}, "pagerange": {"@first": "158", "@last": "172"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.R.", "@_fa": "true", "ce:surname": "Wilson", "ce:indexed-name": "Wilson T.R."}, {"@seq": "2", "ce:initials": "D.Y.", "@_fa": "true", "ce:surname": "Lee", "ce:indexed-name": "Lee D.Y."}, {"@seq": "3", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Berry", "ce:indexed-name": "Berry L."}, {"@seq": "4", "ce:initials": "D.S.", "@_fa": "true", "ce:surname": "Shames", "ce:indexed-name": "Shames D.S."}, {"@seq": "5", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Settleman", "ce:indexed-name": "Settleman J."}]}, "ref-sourcetitle": "Cancer Cell"}}, {"ref-fulltext": "Shames D.S., Carbon J., Walter K., Jubb A.M., Kozlowski C., Januario T., et al. High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck. PLoS One 2013, 8:e56765.", "@id": "18", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck"}, "refd-itemidlist": {"itemid": [{"$": "e56765", "@idtype": "ARTNUM"}, {"$": "84874544754", "@idtype": "SGR"}]}, "ref-volisspag": {"voliss": {"@volume": "8"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.S.", "@_fa": "true", "ce:surname": "Shames", "ce:indexed-name": "Shames D.S."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Carbon", "ce:indexed-name": "Carbon J."}, {"@seq": "3", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Walter", "ce:indexed-name": "Walter K."}, {"@seq": "4", "ce:initials": "A.M.", "@_fa": "true", "ce:surname": "Jubb", "ce:indexed-name": "Jubb A.M."}, {"@seq": "5", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Kozlowski", "ce:indexed-name": "Kozlowski C."}, {"@seq": "6", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Januario", "ce:indexed-name": "Januario T."}], "et-al": null}, "ref-sourcetitle": "PLoS One"}}, {"ref-fulltext": "Felip E., Martinez P. Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers?. Ann. Oncol. 2012, 23:189-192.", "@id": "19", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers?"}, "refd-itemidlist": {"itemid": {"$": "84866758708", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "23"}, "pagerange": {"@first": "189", "@last": "192"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Felip", "ce:indexed-name": "Felip E."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Martinez", "ce:indexed-name": "Martinez P."}]}, "ref-sourcetitle": "Ann. Oncol."}}, {"ref-fulltext": "Azuma K., Komohara Y., Sasada T., Terazaki Y., Ikeda J., Hoshino T., et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci. 2007, 98:1336-1343.", "@id": "20", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy"}, "refd-itemidlist": {"itemid": {"$": "34547780057", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "98"}, "pagerange": {"@first": "1336", "@last": "1343"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Azuma", "ce:indexed-name": "Azuma K."}, {"@seq": "2", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Komohara", "ce:indexed-name": "Komohara Y."}, {"@seq": "3", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Sasada", "ce:indexed-name": "Sasada T."}, {"@seq": "4", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Terazaki", "ce:indexed-name": "Terazaki Y."}, {"@seq": "5", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Ikeda", "ce:indexed-name": "Ikeda J."}, {"@seq": "6", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Hoshino", "ce:indexed-name": "Hoshino T."}], "et-al": null}, "ref-sourcetitle": "Cancer Sci."}}, {"ref-fulltext": "Ceppi P., Volante M., Novello S., Rapa I., Danenberg K.D., Danenberg P.V., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol. 2006, 17:1818-1825.", "@id": "21", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine"}, "refd-itemidlist": {"itemid": {"$": "33845361135", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "17"}, "pagerange": {"@first": "1818", "@last": "1825"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Ceppi", "ce:indexed-name": "Ceppi P."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Volante", "ce:indexed-name": "Volante M."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Novello", "ce:indexed-name": "Novello S."}, {"@seq": "4", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Rapa", "ce:indexed-name": "Rapa I."}, {"@seq": "5", "ce:initials": "K.D.", "@_fa": "true", "ce:surname": "Danenberg", "ce:indexed-name": "Danenberg K.D."}, {"@seq": "6", "ce:initials": "P.V.", "@_fa": "true", "ce:surname": "Danenberg", "ce:indexed-name": "Danenberg P.V."}], "et-al": null}, "ref-sourcetitle": "Ann. Oncol."}}, {"ref-fulltext": "Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andr\u00e9 F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006, 355:983-991.", "@id": "22", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy"}, "refd-itemidlist": {"itemid": {"$": "33748435058", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "355"}, "pagerange": {"@first": "983", "@last": "991"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "K.A.", "@_fa": "true", "ce:surname": "Olaussen", "ce:indexed-name": "Olaussen K.A."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Dunant", "ce:indexed-name": "Dunant A."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Fouret", "ce:indexed-name": "Fouret P."}, {"@seq": "4", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Brambilla", "ce:indexed-name": "Brambilla E."}, {"@seq": "5", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Andr\u00e9", "ce:indexed-name": "Andre F."}, {"@seq": "6", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Haddad", "ce:indexed-name": "Haddad V."}], "et-al": null}, "ref-sourcetitle": "N. Engl. J. Med."}}, {"ref-fulltext": "Friboulet L., Olaussen K.A., Pignon J.P., Shepherd F.A., Tsao M.S., Graziano S., et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N. Engl. J. Med. 2013, 368:1101-1110.", "@id": "23", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "ERCC1 isoform expression and DNA repair in non-small-cell lung cancer"}, "refd-itemidlist": {"itemid": {"$": "84875181563", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "368"}, "pagerange": {"@first": "1101", "@last": "1110"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Friboulet", "ce:indexed-name": "Friboulet L."}, {"@seq": "2", "ce:initials": "K.A.", "@_fa": "true", "ce:surname": "Olaussen", "ce:indexed-name": "Olaussen K.A."}, {"@seq": "3", "ce:initials": "J.P.", "@_fa": "true", "ce:surname": "Pignon", "ce:indexed-name": "Pignon J.P."}, {"@seq": "4", "ce:initials": "F.A.", "@_fa": "true", "ce:surname": "Shepherd", "ce:indexed-name": "Shepherd F.A."}, {"@seq": "5", "ce:initials": "M.S.", "@_fa": "true", "ce:surname": "Tsao", "ce:indexed-name": "Tsao M.S."}, {"@seq": "6", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Graziano", "ce:indexed-name": "Graziano S."}], "et-al": null}, "ref-sourcetitle": "N. Engl. J. Med."}}, {"ref-fulltext": "Yan D., Wei P., An G., Chen W. Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer. J. Cardiothorac. Surg. 2013, 8:149.", "@id": "24", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer"}, "refd-itemidlist": {"itemid": {"$": "84878738921", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "8"}, "pagerange": {"@first": "149"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Yan", "ce:indexed-name": "Yan D."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Wei", "ce:indexed-name": "Wei P."}, {"@seq": "3", "ce:initials": "G.", "@_fa": "true", "ce:surname": "An", "ce:indexed-name": "An G."}, {"@seq": "4", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Chen", "ce:indexed-name": "Chen W."}]}, "ref-sourcetitle": "J. Cardiothorac. Surg."}}, {"ref-fulltext": "Cheong L.H.T., Hui C.W.C., Xu F., Mok T.S.K., Wong C.H. Down-regulation of ERCC1 by EGFR-TKI improves platinum-based chemotherapy efficacy for non-small cell lung cancer (NSCLC). J. Thorac. Oncol. 2014, 9(Suppl. 9):S7-52.", "@id": "25", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Down-regulation of ERCC1 by EGFR-TKI improves platinum-based chemotherapy efficacy for non-small cell lung cancer (NSCLC)"}, "refd-itemidlist": {"itemid": {"$": "85027424978", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "9"}, "pagerange": {"@first": "S7", "@last": "52"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.H.T.", "@_fa": "true", "ce:surname": "Cheong", "ce:indexed-name": "Cheong L.H.T."}, {"@seq": "2", "ce:initials": "C.W.C.", "@_fa": "true", "ce:surname": "Hui", "ce:indexed-name": "Hui C.W.C."}, {"@seq": "3", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Xu", "ce:indexed-name": "Xu F."}, {"@seq": "4", "ce:initials": "T.S.K.", "@_fa": "true", "ce:surname": "Mok", "ce:indexed-name": "Mok T.S.K."}, {"@seq": "5", "ce:initials": "C.H.", "@_fa": "true", "ce:surname": "Wong", "ce:indexed-name": "Wong C.H."}]}, "ref-sourcetitle": "J. Thorac. Oncol."}}, {"ref-fulltext": "Hirsch F.R., Verella-Garcia M., Bunn P.A., Franklin W.A., Dziadziuszko R. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 2006, 24:5034-5042.", "@id": "26", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer"}, "refd-itemidlist": {"itemid": {"$": "33750962024", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "24"}, "pagerange": {"@first": "5034", "@last": "5042"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "F.R.", "@_fa": "true", "ce:surname": "Hirsch", "ce:indexed-name": "Hirsch F.R."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Verella-Garcia", "ce:indexed-name": "Verella-Garcia M."}, {"@seq": "3", "ce:initials": "P.A.", "@_fa": "true", "ce:surname": "Bunn", "ce:indexed-name": "Bunn P.A."}, {"@seq": "4", "ce:initials": "W.A.", "@_fa": "true", "ce:surname": "Franklin", "ce:indexed-name": "Franklin W.A."}, {"@seq": "5", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Dziadziuszko", "ce:indexed-name": "Dziadziuszko R."}]}, "ref-sourcetitle": "J. Clin. Oncol."}}, {"ref-fulltext": "Moecks J., Soulieres D., Klughammer B. ReadMax-a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild-type non-small-cell lung cancer. J. Pathol. Clin. Res. 2015, 1:134-143.", "@id": "27", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "ReadMax-a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild-type non-small-cell lung cancer"}, "refd-itemidlist": {"itemid": {"$": "84966709328", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "1"}, "pagerange": {"@first": "134", "@last": "143"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Moecks", "ce:indexed-name": "Moecks J."}, {"@seq": "2", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Soulieres", "ce:indexed-name": "Soulieres D."}, {"@seq": "3", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Klughammer", "ce:indexed-name": "Klughammer B."}]}, "ref-sourcetitle": "J. Pathol. Clin. Res."}}]}}}}, "affiliation": [{"affiliation-city": "Bangkok", "@id": "60199575", "affilname": "Siriraj Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575", "affiliation-country": "Thailand"}, {"affiliation-city": "Taipei", "@id": "60073385", "affilname": "National Taiwan University Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073385", "affiliation-country": "Taiwan"}, {"affiliation-city": "Manila", "@id": "60071478", "affilname": "Philippine General Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071478", "affiliation-country": "Philippines"}, {"affiliation-city": "Quezon City", "@id": "60071470", "affilname": "Lung Center of the Philippines", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071470", "affiliation-country": "Philippines"}, {"affiliation-city": "Guangzhou", "@id": "60069718", "affilname": "Guangdong Provincial People\u2019s Hospital of Southern Medical University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069718", "affiliation-country": "China"}, {"affiliation-city": "Goyang", "@id": "60068716", "affilname": "National Cancer Center, Gyeonggi", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60068716", "affiliation-country": "South Korea"}, {"affiliation-city": "San Francisco", "@id": "60026209", "affilname": "Genentech, Inc", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026209", "affiliation-country": "United States"}, {"affiliation-city": "Bangkok", "@id": "60022183", "affilname": "King Chulalongkorn Memorial Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183", "affiliation-country": "Thailand"}, {"affiliation-city": "Basel", "@id": "60008201", "affilname": "F. Hoffmann-La Roche AG", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008201", "affiliation-country": "Switzerland"}, {"affiliation-city": "Hong Kong", "@id": "60002798", "affilname": "Chinese University of Hong Kong", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002798", "affiliation-country": "Hong Kong"}, {"affiliation-city": "Chaing Mai", "@id": "60000881", "affilname": "Chiang Mai University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881", "affiliation-country": "Thailand"}, {"affiliation-city": "Pasig, Metro Manila", "@id": "127844345", "affilname": "Rizal Medical Center", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127844345", "affiliation-country": "Philippines"}], "coredata": {"srctype": "j", "eid": "2-s2.0-84966701371", "dc:description": "Objectives: The FASTACT-2 study of intercalated erlotinib with chemotherapy in Asian patients found that EGFR mutations were the main driver behind the significant progression-free survival (PFS) benefit noted in the overall population. Further exploratory biomarker analyses were conducted to provide additional insight. Materials and methods: This multicenter, randomized, placebo-controlled, double-blind, phase III study investigated intercalated first-line erlotinib or placebo with gemcitabine/platinum, followed by maintenance erlotinib or placebo, for patients with stage IIIB/IV non-small cell lung cancer (NSCLC). Provision of samples for biomarker analysis was encouraged but not mandatory. The following biomarkers were analyzed (in order of priority): EGFR mutation by cobas\u00ae test, KRAS mutation by cobas\u00ae KRAS test, HER2 by immunohistochemistry (IHC), HER3 by IHC, ERCC1 by IHC, EGFR gene copy number by fluorescence in-situ hybridization (FISH) and EGFR by IHC. All subgroups were assessed for PFS (primary endpoint), overall survival (OS), non-progression rate and objective response rate. Results: Overall, 256 patients provided samples for analysis. Considerable overlap was noted among biomarkers, except for EGFR and KRAS mutations, which are mutually exclusive. Other than EGFR mutations (p < 0.0001), no other biomarkers were significantly predictive of outcomes in a treatment-by-biomarker interaction test, although ERCC1 IHC-positive status was predictive of improved OS for the erlotinib arm versus placebo in EGFR wild-type patients (median 18.4 vs 9.5 months; hazard ratio [HR] HR = 0.32, 95% confidence intervals [CI]: 0.14-0.69, p = 0.0024). Conclusion: Activating EGFR mutations were predictive for improved treatment outcomes with a first-line intercalated regimen of chemotherapy and erlotinib in NSCLC. ERCC1 status may have some predictive value in EGFR wild-type disease, but requires further investigation.", "pubmed-id": "27393499", "prism:coverDate": "2016-08-01", "prism:aggregationType": "Journal", "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/84966701371", "dc:creator": {"author": [{"ce:given-name": "Tony", "preferred-name": {"ce:given-name": "Tony", "ce:initials": "T.", "ce:surname": "Mok", "ce:indexed-name": "Mok T."}, "@seq": "1", "ce:initials": "T.", "@_fa": "true", "affiliation": {"@id": "60002798", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002798"}, "ce:surname": "Mok", "@auid": "7006561460", "author-url": "https://api.elsevier.com/content/author/author_id/7006561460", "ce:indexed-name": "Mok T."}]}, "link": [{"@_fa": "true", "@rel": "self", "@href": "https://api.elsevier.com/content/abstract/scopus_id/84966701371"}, {"@_fa": "true", "@rel": "scopus", "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84966701371&origin=inward"}, {"@_fa": "true", "@rel": "scopus-citedby", "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84966701371&origin=inward"}], "source-id": "12391", "pii": "S0169500216303099", "citedby-count": "20", "prism:volume": "98", "subtype": "ar", "dc:title": "Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer", "openaccess": "1", "prism:issn": "18728332 01695002", "publishercopyright": "\u00a9 2016 The Authors.", "subtypeDescription": "Article", "prism:publicationName": "Lung Cancer", "prism:pageRange": "1-8", "prism:endingPage": "8", "openaccessFlag": "true", "prism:doi": "10.1016/j.lungcan.2016.04.023", "prism:startingPage": "1", "dc:identifier": "SCOPUS_ID:84966701371", "dc:publisher": "Elsevier Ireland Ltd"}, "idxterms": {"mainterm": [{"$": "Antineoplastic Combined Chemotherapy Protocols", "@weight": "b", "@candidate": "n"}, {"$": "Biomarkers, Tumor", "@weight": "a", "@candidate": "n"}, {"$": "Carcinoma, Non-Small-Cell Lung", "@weight": "b", "@candidate": "n"}, {"$": "Deoxycytidine", "@weight": "b", "@candidate": "n"}, {"$": "Erlotinib Hydrochloride", "@weight": "b", "@candidate": "n"}, {"$": "Female", "@weight": "b", "@candidate": "n"}, {"$": "Humans", "@weight": "b", "@candidate": "n"}, {"$": "Kaplan-Meier Estimate", "@weight": "b", "@candidate": "n"}, {"$": "Lung Neoplasms", "@weight": "b", "@candidate": "n"}, {"$": "Male", "@weight": "b", "@candidate": "n"}, {"$": "Neoplasm Staging", "@weight": "b", "@candidate": "n"}, {"$": "Platinum", "@weight": "b", "@candidate": "n"}, {"$": "Treatment Outcome", "@weight": "b", "@candidate": "n"}]}, "language": {"@xml:lang": "eng"}, "authkeywords": {"author-keyword": [{"@_fa": "true", "$": "Biomarkers"}, {"@_fa": "true", "$": "EGFR"}, {"@_fa": "true", "$": "Erlotinib"}, {"@_fa": "true", "$": "NSCLC"}]}, "subject-areas": {"subject-area": [{"@_fa": "true", "$": "Oncology", "@code": "2730", "@abbrev": "MEDI"}, {"@_fa": "true", "$": "Pulmonary and Respiratory Medicine", "@code": "2740", "@abbrev": "MEDI"}, {"@_fa": "true", "$": "Cancer Research", "@code": "1306", "@abbrev": "BIOC"}]}, "authors": {"author": [{"ce:given-name": "Tony", "preferred-name": {"ce:given-name": "Tony", "ce:initials": "T.", "ce:surname": "Mok", "ce:indexed-name": "Mok T."}, "@seq": "1", "ce:initials": "T.", "@_fa": "true", "affiliation": {"@id": "60002798", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002798"}, "ce:surname": "Mok", "@auid": "7006561460", "author-url": "https://api.elsevier.com/content/author/author_id/7006561460", "ce:indexed-name": "Mok T."}, {"ce:given-name": "Guia", "preferred-name": {"ce:given-name": "Guia", "ce:initials": "G.", "ce:surname": "Ladrera", "ce:indexed-name": "Ladrera G."}, "@seq": "2", "ce:initials": "G.", "@_fa": "true", "affiliation": {"@id": "60071470", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071470"}, "ce:surname": "Ladrera", "@auid": "56287672600", "author-url": "https://api.elsevier.com/content/author/author_id/56287672600", "ce:indexed-name": "Ladrera G."}, {"ce:given-name": "Vichien", "preferred-name": {"ce:given-name": "Vichien", "ce:initials": "V.", "ce:surname": "Srimuninnimit", "ce:indexed-name": "Srimuninnimit V."}, "@seq": "3", "ce:initials": "V.", "@_fa": "true", "affiliation": {"@id": "60199575", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575"}, "ce:surname": "Srimuninnimit", "@auid": "6602745742", "author-url": "https://api.elsevier.com/content/author/author_id/6602745742", "ce:indexed-name": "Srimuninnimit V."}, {"ce:given-name": "Virote", "preferred-name": {"ce:given-name": "Virote", "ce:initials": "V.", "ce:surname": "Sriuranpong", "ce:indexed-name": "Sriuranpong V."}, "@seq": "4", "ce:initials": "V.", "@_fa": "true", "affiliation": {"@id": "60022183", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183"}, "ce:surname": "Sriuranpong", "@auid": "6603599644", "author-url": "https://api.elsevier.com/content/author/author_id/6603599644", "ce:indexed-name": "Sriuranpong V."}, {"ce:given-name": "Chong-Jen", "preferred-name": {"ce:given-name": "Chong Jen", "ce:initials": "C.J.", "ce:surname": "Yu", "ce:indexed-name": "Yu C.J."}, "@seq": "5", "ce:initials": "C.-J.", "@_fa": "true", "affiliation": {"@id": "60073385", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073385"}, "ce:surname": "Yu", "@auid": "7404977466", "author-url": "https://api.elsevier.com/content/author/author_id/7404977466", "ce:indexed-name": "Yu C.-J."}, {"ce:given-name": "Sumitra", "preferred-name": {"ce:given-name": "Sumitra", "ce:initials": "S.", "ce:surname": "Thongprasert", "ce:indexed-name": "Thongprasert S."}, "@seq": "6", "ce:initials": "S.", "@_fa": "true", "affiliation": {"@id": "60000881", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881"}, "ce:surname": "Thongprasert", "@auid": "7003592958", "author-url": "https://api.elsevier.com/content/author/author_id/7003592958", "ce:indexed-name": "Thongprasert S."}, {"ce:given-name": "Jennifer", "preferred-name": {"ce:given-name": "Jennifer", "ce:initials": "J.", "ce:surname": "Sandoval-Tan", "ce:indexed-name": "Sandoval-Tan J."}, "@seq": "7", "ce:initials": "J.", "@_fa": "true", "affiliation": {"@id": "60071478", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071478"}, "ce:surname": "Sandoval-Tan", "@auid": "55762538000", "author-url": "https://api.elsevier.com/content/author/author_id/55762538000", "ce:indexed-name": "Sandoval-Tan J."}, {"ce:given-name": "Jin Soo", "preferred-name": {"ce:given-name": "Jin Soo", "ce:initials": "J.S.", "ce:surname": "Lee", "ce:indexed-name": "Lee J.S."}, "@seq": "8", "ce:initials": "J.S.", "@_fa": "true", "affiliation": {"@id": "60068716", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60068716"}, "ce:surname": "Lee", "@auid": "42161717300", "author-url": "https://api.elsevier.com/content/author/author_id/42161717300", "ce:indexed-name": "Lee J.S."}, {"ce:given-name": "Fatima", "preferred-name": {"ce:given-name": "Fatima", "ce:initials": "F.", "ce:surname": "Fuerte", "ce:indexed-name": "Fuerte F."}, "@seq": "9", "ce:initials": "F.", "@_fa": "true", "affiliation": {"@id": "127844345", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127844345"}, "ce:surname": "Fuerte", "@auid": "55762400200", "author-url": "https://api.elsevier.com/content/author/author_id/55762400200", "ce:indexed-name": "Fuerte F."}, {"ce:given-name": "David S.", "preferred-name": {"ce:given-name": "David S.", "ce:initials": "D.S.", "ce:surname": "Shames", "ce:indexed-name": "Shames D.S."}, "@seq": "10", "ce:initials": "D.S.", "@_fa": "true", "affiliation": {"@id": "60026209", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026209"}, "ce:surname": "Shames", "@auid": "34573130000", "author-url": "https://api.elsevier.com/content/author/author_id/34573130000", "ce:indexed-name": "Shames D.S."}, {"ce:given-name": "Barbara", "preferred-name": {"ce:given-name": "Barbara", "ce:initials": "B.", "ce:surname": "Klughammer", "ce:indexed-name": "Klughammer B."}, "@seq": "11", "ce:initials": "B.", "@_fa": "true", "affiliation": {"@id": "60008201", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008201"}, "ce:surname": "Klughammer", "@auid": "36777629300", "author-url": "https://api.elsevier.com/content/author/author_id/36777629300", "ce:indexed-name": "Klughammer B."}, {"ce:given-name": "Matt", "preferred-name": {"ce:given-name": "Matt", "ce:initials": "M.", "ce:surname": "Truman", "ce:indexed-name": "Truman M."}, "@seq": "12", "ce:initials": "M.", "@_fa": "true", "affiliation": {"@id": "60008201", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008201"}, "ce:surname": "Truman", "@auid": "57189251756", "author-url": "https://api.elsevier.com/content/author/author_id/57189251756", "ce:indexed-name": "Truman M."}, {"ce:given-name": "Pablo", "preferred-name": {"ce:given-name": "Pablo", "ce:initials": "P.", "ce:surname": "Perez-Moreno", "ce:indexed-name": "Perez-Moreno P."}, "@seq": "13", "ce:initials": "P.", "@_fa": "true", "affiliation": {"@id": "60008201", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008201"}, "ce:surname": "Perez-Moreno", "@auid": "54397369600", "author-url": "https://api.elsevier.com/content/author/author_id/54397369600", "ce:indexed-name": "Perez-Moreno P."}, {"ce:given-name": "Yi-Long", "preferred-name": {"ce:given-name": "Yi Long", "ce:initials": "Y.L.", "ce:surname": "Wu", "ce:indexed-name": "Wu Y.L."}, "@seq": "14", "ce:initials": "Y.-L.", "@_fa": "true", "affiliation": {"@id": "60069718", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069718"}, "ce:surname": "Wu", "@auid": "55569782000", "author-url": "https://api.elsevier.com/content/author/author_id/55569782000", "ce:indexed-name": "Wu Y.-L."}]}}}